ArticleMolecules (Basel, Switzerland)2026
From Yufeining to Kaempferol: Multi-Target Anti-Inflammatory, Antioxidant, and Anti-Apoptotic Mechanisms Targeting the STAT3-TP53-IL1B Signaling Network in COPD Therapy.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is a heterogeneous syn-drome which leads to irreversible and progressive airflow limitation. Yufeining (YFN) is a Chinese herbal formula employed for treating COPD; however, the key ingredients and mechanisms are not fully defined.
methodsThe key bioactive compounds and their corresponding targets of YFN were recognized using the network pharmacology method. The CIBERSORT algorithm was employed to identify the immune infiltration profiles in COPD and their correlation with the principal targets. Through the COPD mouse model, the effects of kaempferol on inflammation, oxidative damage, and apoptosis were evaluated. The BEAS-2B cells treated with cigarette smoke extract (CSE) were used to assess the protective effects of kaempferol against inflammation, oxidative stress, and apoptosis. Using flow cytometry, the anti-apoptosis effects of kaempferol were analyzed. Transcriptomic Analysis was performed to investigate the transcriptional changes in CSE-induced BEAS-2B cells.
resultsKaempferol is a key compound of YFN, and STAT3, TP53, and IL1B are predicted to be the core targets of YFN for COPD treatment. Immune infiltration analysis revealed a significant correlation between STAT3-TP53-IL1B signaling network and inflammatory cell infiltration. Kaempferol alleviated inflammation, oxidative damage, and apoptosis in the COPD mouse model. In CSE-induced BEAS-2B cells, kaempferol inhibited the inflammatory response, oxidative damage, and apoptosis. The transcriptome sequencing revealed a total of 223 differentially expressed genes. After treating with kaempferol, the transcriptional levels of STAT3 significantly increased, while those of TP53 and IL1B significantly decreased.
conclusionsKaempferol can exert therapeutic effects against COPD by inhibiting inflammatory response and oxidative damage, and reducing cell apoptosis. Furthermore, this study indicated the therapeutic mechanism of YFN in COPD involves potentially targeting the STAT3-TP53-IL1B signaling network through kaempferol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.